IP Library Granted Patent US 10,947,517
Granted Patent B2
US 10,947,517 · App. 16/790,399 · Granted Mar 16, 2021

CRISPR/Cas fusion proteins and systems

Inventor: Fuqiang Chen (St. Louis, MO)
Assignee: Sigma-Aldrich Co. LLC
C12N9/22C07K14/205C07K14/31C07K14/315C12N15/113C07K2319/09
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,947,517
App. No.
16/790,399
Granted
Mar 16, 2021
Kind
B2
Abstract

Engineered Cas9 systems are disclosed herein. For example, Cas9-marker fusion proteins are provided. Peptide linkers which facilitate fusion of heterologous proteins to CRISPR proteins in ways that preserve CRISPR functionality are also provided.

Claims (15)

1. A fusion protein comprising a Streptococcus pyogenes Cas9 protein; a marker protein; at least one first linker between the Cas9 protein and the marker protein, wherein the at least one first linker comprises SEQ ID NO:35; and a first heterologous domain that is a nuclear localization signal; wherein the fusion protein is a nuclease and cleaves both strands of a double-stranded sequence, is a nickase and cleaves one strand of a double-stranded sequence, or has no nuclease or nickase activity.

2. The fusion protein of claim 1 , wherein the marker protein is at the C-terminus of the fusion protein.

3. The fusion protein of claim 1 , further comprising an optional second linker,

wherein the nuclear localization signal, the marker protein, the first linker, the optional second linker (if present), and the Cas9 protein are arranged in the following order (N-terminus to C-terminus):

marker protein-first linker-nuclear localization signal-Cas9 protein;

marker protein-nuclear localization signal-first linker-Cas9 protein;

nuclear localization signal-marker protein-first linker-Cas9 protein;

marker protein-first linker-nuclear localization signal-first linker-Cas9 protein; or

nuclear localization signal-second linker-marker protein-first linker-Cas9 protein.

4. The fusion protein of claim 3 , wherein the nuclear localization signal, the marker protein, the first linker, and the Cas9 protein are arranged in the following order (N-terminus to C-terminus):

marker protein-first linker-nuclear localization signal-Cas9 protein.

5. The fusion protein of claim 1 , further comprising at least one additional heterologous domain other than the first heterologous domain that is a nuclear localization signal, wherein the at least one additional heterologous domain is a cell-penetrating domain, a chromatin modulating motif, an epigenetic modification domain, a transcriptional regulation domain, an RNA aptamer binding domain, or combination thereof.

6. The fusion protein of claim 1 , wherein the marker protein has an amino acid sequence comprising SEQ ID NO:19 or 20.

7. The fusion protein of claim 1 , wherein the marker protein has an amino acid sequence consisting of SEQ ID NO:19 or 20.

8. The fusion protein of claim 1 , wherein the fusion protein has an amino acid sequence comprising SEQ ID NO:48, 49, or 50.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2020
From: CHEN, FUQIANG
To: SIGMA-ALDRICH CO. LLC
Reel/Frame 052093/0674 →
Continuity (2)
Provisional Application 62806708 · Feb 15, 2019
Related Publication 20200263155A1 · Aug 20, 2020
Cited By (1)
US 12,201,699